Increased risk for cervical intraepithelial neoplasia (CIN) in human immunodeficiency virus (HlV)-infected women may be explained by repeated positivity of human papillomavirus (HPV) infection facilitated by HIV infection and related immunosuppression. As part of a longitudinal study with semiannual examinations, 268 women in Baltimore, Maryland (of whom 184 were HIV+), provided 1,426 cervicovaginal lavage specimens tested for HPV DNA by a polymerase chain reaction-based assay between 1992 and 1998. HPV positivity and time to HPV clearance according to HIV serostatus and CD4* cell count were compared using models for correlated binary data and survival analysis. Of the 187 participants who had at least one positive measurement, the probability of subsequent HPV positivity among HIV-women and HIV+ women with CD4* £200 and <200 cells/pJ was 47.5%, 78.7%, and 92.9% (p < 0.001). Within-women HPV results were correlated (i.e., clustered) in each group (p < 0.01). Compared with HIV-participants, the relative incidence of HPV clearance was 0.29 and 0.10 among HIV+ women with CD4 + £200 and <200 cells/u.l (p < 0.001). At the end of follow-up, 11 women had biopsy-confirmed CIN. The association of HIV and CIN (p = 0.014) was fully explained by repeated HPV positivity induced by HIV infection (p = 0.648). Reversal of immunosuppression following potent antiretroviral therapy must be expected to have a dramatic impact on HIV-related CIN. Am J Epidemiol 2000; 151:1148-57. cervical intraepithelial neoplasia; HIV; immunosuppression; papillomavirus, human During the past two decades, epidemiologic evidence and laboratory evidence have converged to establish and characterize the causal association of genital human papillomavirus (HPV) infection and cervical intraepithelial neoplasia (CIN) (1). In addition, variables previously reported as risk factors for CIN, such as age of first intercourse, number of lifetime sexual partners, and sexual behavior of male partners, have more recently been shown to be risk factors for the acquisition of HPV infection (2). An unresolved question in HPV research, however, is why only a frac- tion of women infected with HPV develop cancer precursor lesions and an even smaller fraction develop invasive cervical cancer.
During the past two decades, epidemiologic evidence and laboratory evidence have converged to establish and characterize the causal association of genital human papillomavirus (HPV) infection and cervical intraepithelial neoplasia (CIN) (1) . In addition, variables previously reported as risk factors for CIN, such as age of first intercourse, number of lifetime sexual partners, and sexual behavior of male partners, have more recently been shown to be risk factors for the acquisition of HPV infection (2) . An unresolved question in HPV research, however, is why only a frac-tion of women infected with HPV develop cancer precursor lesions and an even smaller fraction develop invasive cervical cancer.
With the advent of the human immunodeficiency virus (HIV) pandemic, initial case reports and subsequent longitudinal studies identified an increased risk of CIN among those women who were both infected with HTV and immunosuppressed (3, 4) . In addition, HTV-seropositive women were observed to have a higher prevalence of HPV infection than their HTVseronegative counterparts (5) (6) (7) . HTV-associated systemic immunosuppression has been hypothesized as a mechanism to explain this increased risk of CIN in HIV-seropositive women (8) . Possible impacts of immunosuppression on the natural history of HPV include the reactivation of latent infections and the establishment of chronic or persistent infections (5, 9) .
The purpose of our study was to determine whether HIV infection and immunosuppression facilitate repeated HPV positivity and whether this positivity could explain the increased incidence of CIN observed in HTV-infected women. Specifically, we explored the possibility that HPV infection was not only more common, but also less transient, in immunosuppressed HIV-seropositive women. Further, we considered the joint effects of HIV infection and HPV positivity on increased rates of CIN. Specifically, we evaluated whether the mechanism by which HIV infection relates to CIN is fully explained by repeated HPV positivity induced by HTV-associated immunosuppression.
The study was conducted within a population-based longitudinal study (AIDS (acquired immunodeficiency syndrome) Link to Intravenous Drug Experience (ALIVE)) in Baltimore, Maryland. Toward the goal of understanding the natural history of HTV infection in injection drug users, the ALIVE study has conducted semiannual questionnaire interviews and physical examinations for over 10 years. HTV serostatus and level of immunosuppression were associated with both HPV infection and cytologic abnormalities at study baseline (10) . The prospective collection of serum and cervicovaginal lavage specimens, coupled with the implementation of colposcopic examinations at the end of study follow-up, made this cohort an ideal setting in which to investigate the hypotheses of direct interest to this study.
MATERIALS AND METHODS

Study population
The study population consisted of 84 HTV-seronegative and 184 HTV-seropositive women under followup in the ALIVE cohort. The organization, recruitment methods, and data collection procedures for the ALIVE study, as well as its rationale, have previously been described (11) . In summary, 2,921 injection drug users in Baltimore, Maryland, were recruited using extensive community outreach techniques between February 1988 and March 1989. Participants had to be 18 years or older, have a history of injection drug use during the previous 11 years, and have no history of an acquired immunodeficiency syndrome-defining illness at the time of recruitment. All individuals who were HTV seropositive at baseline, along with a sample of HTV-seronegative individuals, were invited to enroll in the follow-up study. Semiannual clinic visits consist of a structured interview on demographic and behavioral characteristics, a complete physical examination, and phlebotomy. Between September 1992 and September 1997, 268 women in study follow-up consented to an expanded physical examination that included the semiannual collection of cervical smears and cervicovaginal lavage specimens. In order to evaluate jointly the impact of both HIV-associated immunosuppression and repeated HPV positivity on cervical neoplasia, we performed colposcopic examinations on 107 of the 191 study participants in active follow-up who responded to a letter of invitation during a 5-month period in early 1998.
Data collection
Variables of primary interest to this study included baseline HTV serostatus and CD4 + cell count, HPV status at baseline and at all subsequent study visits, and cervical disease status as assessed by colposcopy and biopsy at the end of the follow-up for this study. For the purposes of this analysis, baseline was defined as the visit at which HPV measurements were first collected.
HIV-1 antibodies were detected using enzyme-linked immunosorbent assay and confirmed by Western blot. T-cell subsets were measured in specimens of heparinized whole blood stained with monoclonal antibodies, using the whole blood method of Hoffman et al. (12) , as modified by Giorgi et al. (13) . Cervical smears were collected using a cytobrush and Ayre's spatula and classified according to the Bethesda Classification System. A total of 1,426 cervicovaginal lavage specimens were collected using 10 ml of normal saline and assayed for HPV using MY09/MY11/HB01 LI consensus primer polymerase chain reaction, with both generic and type-specific probes (10, 14) . As delineated in table 1, we grouped HPV types into high-, intermediate-, and low-risk categories (15) . Specimens that were negative for both beta globin and HPV were eliminated from analyses. Abnormal colposcopic findings were further evaluated by the collection of colposcopically directed biopsies. Endocervical curettage specimens were collected if the transformation zone could not be adequately visualized.
The study was approved by the Institutional Review Board of The Johns Hopkins School of Hygiene and Public Health and the ALIVE Community Advisory Board.
Statistical analyses
Baseline cross-sectional analyses comparing HTVseronegative and HTV-seropositive participants were done by constructing contingency tables and testing for homogeneity and trend. Study participants were categorized into three groups, based on HTV serostatus and two categories of CD4 + cell count, with a cutoff of 200 cells/u.1 distinguishing those who were moderately and severely immunosuppressed. The relevant group to assess repeated HPV positivity was composed of the 187 women who had at least one HPV-positive measurement followed by one or more follow-up assessments of infection status.
We characterized repeated HPV positivity using two approaches. First, repeated HPV measurements were analyzed using logistic regression models for correlated observations (16) . These beta binomial models are an extension of logistic regression models and include two parameters, one that measures the proba- 26, 39 , and 40 were not detected in any specimen. Participants who tested positive for multiple types were counted separately for the calculation of type-specific rates but counted only once for "any" rates. Participants who had HPVs belonging to multiple risk categories were assigned to the higher risk category. One participant had a missing CD4* cell count.
bility of being HPV positive at any point in follow-up and another that can handle and quantify the correlation of HPV measurements at different visits of a single participant (i.e., intraclass correlation or clustering coefficient). These models were applied to describe both the probability and clustering of HPV infection, according to HIV positivity and CD4 + cell count. The primary outcome for this analysis was the proportion of all HPV measurements that were positive. We tested the homogeneity of these parameters among the three study groups.
The second approach used survival analysis methods to evaluate the time to HPV clearance (17) . Time was measured from the first time a woman tested positive for HPV and the event, HPV clearance, was defined as the first time a woman tested negative for HPV following the first positive HPV measurement. Time to HPV clearance was measured by discrete 6-month intervals. Those who never cleared were analyzed as censored observations. Missed visits between HPV-positive visits were considered HPV positive, but this assumption was required for only 7 percent of all observations. Cox proportional hazards models were used to account for the length of study follow-up and to determine the incidence (i.e., hazards) of HPV clearance according to HIV serostatus and level of immunosuppression. Since the outcome of interest, time to HPV clearance, is desirable, relative hazards below one indicate increased risk.
While our primary analyses used generic HPV infection as the outcome, proportional hazards models were also applied to calculate type-specific estimates of HPV clearance for each of the four high-risk HPVs. We obtained estimates and standard errors for each type and then calculated an overall average for the combined effects using standard methods for weighted (according to the inverse of the variance) averages.
Exact methods for the analysis of 2 x 2 tables were used to determine the association between HTV infection and cervical neoplasia. We calculated the HTV prevalence among those with cervical neoplasia relative to the HTV prevalence among those without cervical neoplasia. In order to account for the role of HPV positivity, we stratified by the proportion of all HPV measurements that were positive. We then determined whether the association between HTV infection and cervical neoplasia remained after incorporating the role of HPV positivity.
RESULTS
Baseline characteristics
The study population of 84 HTV-seronegative and 184 HTV-seropositive participants had a median age of 36.2 years at their initial visit, and 93.2 percent of participants were African American. In this cohort of injection drug users, no significant demographic or behavioral characteristics differed by HIV serostatus, including number of sexual partners and smoking status. While 13.4 percent of HTV-seropositive women had baseline cervical smear abnormalities of squamous intraepithelial lesions or above, only 2.4 percent of HTV-seronegative women had such abnormalities (p < 0.001). The relative prevalence of HPV among HTV-seropositive as compared with HTV-seronegative women was 2. 
Repeated positivity of HPV infection
Study participants had a median of six visits (ranging from one to 10) at which HPV status was measured. Although follow-up was slightly higher for HTV-seronegative (median = 6) than HTV-seropositive (median = 5 for both subgroups of HTV-seropositive women) participants, 35 percent of seropositive women, including those who were severely immunosuppressed, had six or more study visits at which HPV status was measured.
Of 84 HTV-seronegative and 184 HTV-seropositive women, 56.0 percent and 88.0 percent, respectively, had at least one positive HPV measurement (p < 0.001). The subset pertinent to the longitudinal analysis was composed of the 43 (51.2 percent) HTVseronegative participants, 113 (77.4 percent) HTVseropositive participants with CD4 + cell counts ^200 cells/(i.l, and 31 (83.8 percent) HTV-seropositive participants with CD4 + cell counts <200 cells/|il, who had at least one positive HPV measurement during follow-up and who had samples collected after the first positive measurement. Figure 1 describes levels of HPV positivity, that is, the proportion of all measurements that were positive, among the three study groups. The level of immunosuppression, as measured by HTV serostatus and CD4 + cell count, was found to be associated in a dose-response fashion with full HPV positivity, that is, the detection of one or more HPV types at every study visit. While only 25.6 percent (11/43) of HTV-seronegative participants had such full positivity, 59.3 percent (67/113) and 83.9 percent (26/31) of moderately and severely immunosuppressed HTV-seropositive participants, respectively, had full HPV positivity. The data further suggest that, among the severely immunosuppressed, once an HPV infection occurred, the likelihood of clearing infection was low; that is, 83.9 percent of the 31 women had full HPV positivity following an initial infection (figure 1). Among HTVseronegative participants, however, 27.9 percent (12/43) had no HPV positivity after testing positive the first time.
To assess the significance of the trends observed in figure 1 , we used random effects logistic regression models. Table 2 describes the results given by these models and quantifies the trends observed in figure 1 : a strong dose-response association of HTV serostatus and level of immunosuppression with the probability of HPV infection at any point in follow-up (p < 0.001). While measurements were strongly correlated in each of the three groups {p < 0.01), there was no indication of a difference in clustering between groups {p = 0.851). When we examined the probability and clustering of high-risk HPVs, we observed similar trends. The probability of infection was 44.5 percent among the 10 HTV-seronegative participants, 58. 20 HTV-seropositive participants with CD4 + cell counts <200 cells/nl (p = 0.058). HPV measurements were correlated in all three groups.
While the majority (74.4 percent) of HTV-seronegative participants cleared HPV infection during study followup, only 16.1 percent of severely immunosuppressed HTV-seropositive participants were similarly able to clear their infection (figure 2). We found that the incidence of HPV clearance varied significantly between study groups {p < 0.001). As compared with HTVseronegative participants, the relative incidence of HPV clearance was 0.29 and 0.10 among HTV-seropositive participants with CD4 + cell counts £200 cells/jiJ and <200 cells/nl, respectively. HTV-seropositive partici- • p < 0.01, where the null is that there is no clustering, that is, no con-elation between repeated HPV measurements.
pants with CD4 + cell counts between 200 and 500 cells/|il and those with CD4 + cell counts >500 cells/ul had a similar incidence of HPV clearance and therefore were not assessed separately.
To investigate more closely the question of typespecific persistence, we performed a separate analysis for each of the high-risk HPVs and determined the incidence of HPV clearance among moderately and severely immunosuppressed HTV-seropositive women. Combining the estimates in a weighted fashion, we found that the overall incidence of clearing a high-risk HPV was 0.37 and 0.26 for HTV-seropositive women with CD4 + £200 cells/^il and CD4 + <200 cells/|ll, respectively. The results of these analyses, illustrated in table 3, confirmed our primary inferences.
Cervical neoplasia and repeated HPV positivity
From the 107 women who had colposcopies, 23 cervical biopsies and 56 endocervical curettage specimens were collected. There were no significant demographic differences between women with and without a colposcopy. Histopathologic diagnosis of biopsy specimens indicated that 11 women had cervical intraepithelial lesions (CIN). Of these, seven had lowgrade lesions and four had high-grade lesions. At baseline, the median age of these 11 participants was 35 years, all were current smokers, and eight were current injection drug users. All 11 women were HTV seropositive, with a median CD4 + cell count of 253 cells/fil. It is of note that nine of the 11 participants with CIN had full HPV positivity; that is, they tested positive for HPV at all follow-up visits. Table 4 shows the relative prevalence of HTV infection among the 11 participants with CIN versus the 96 participants with normal colposcopic examinations. Overall, women with neoplasia were 1.63 times more likely than were women without neoplasia to be HTV seropositive (p = 0.014). In order to assess whether the relation of HTV and neoplasia was explained by repeated HPV positivity, participants were stratified into four categories, based on the proportion of all HPV measurements that were positive. After this stratification and formal adjustment for repeated HPV positivity, the observed association between HIV infection and cervical neoplasia became negligible (p = 0.648). On the other hand, the independent association between repeated HPV positivity and cervical neoplasia showed a strong dose-response relation. At the extremes, 25.7 percent (9/35) of women with full positivity had CIN, while none (0/20) of the women with no HPV infection in follow-up had cervical neoplasia (p for trend < 0.001). 
DISCUSSION
We found that systemic immunosuppression plays a substantial role in increasing the likelihood of repeated HPV positivity and that it may explain much of the excess risk of cervical neoplasia observed among HTVseropositive women. HPV infection was not only more common but also less "transient" in immunosuppressed HTV-seropositive women. This confirms previous observations that HTV-infected women are more likely to have concurrent HPV infection (5-7) and that immunosuppression increases the likelihood of repeated detection of HPV DNA in cervicovaginal lavage specimens (18) . Most importantly, we demonstrated that the increased risk of CIN among HTVseropositive women could be explained to a large extent by the repeated positivity of the etiologic agent of CIN, namely HPV.
In the broader epidemiologic picture of cervical disease, findings across several case-control studies have demonstrated strong associations between HPV and CIN (19, 20) . An important aspect of these studies is that, while nearly all women with CIN have concurrent HPV infection, only a small proportion of those infected with HPV develop CIN (21) . This suggests that additional, as yet unidentified characteristics might explain the divergent experiences of HPVinfected women (22) .
In the wake of the HTV pandemic and the welldocumented observation that HIV-infected women are at increased risk for CIN, a related question has been raised, namely, why the natural history of HPV infection differs between HTV-seropositive and HTVseronegative women. Our data are consistent with the mechanism that immunosuppression modulates CIN risk, through repeated HPV positivity and extended exposure to the primary etiologic agent of cervical neoplasia. Notably, it is the severity of HTV-associated immunosuppression that has let us assess this mechanism, by creating a setting in which persistence is common among a large number of women.
It has been suggested that persistent HPV infection may be necessary for the development of cervical neoplasia, and several investigators working with repeated HPV measurements in recent years have examined the phenomenon of persistence as both an outcome of HTVassociated immunosuppression and a predictor of cervical smear abnormalities. For the most part, however, the determinants of HPV persistence are unknown, although it has been found that older women are more likely to have persistent HPV infection, and that highrisk HPVs (14) , particularly HPV-16 (23) , are more likely to persist. A study in New York found that HTV positivity, immunosuppression, less than 12 years of education, and injection drug use were associated with HPV persistence (18) . More recently, it was noted that, among women with an oncogenic HPV at baseline, HTV-seropositive women were more likely than were HTV-seronegative women to remain infected with HPV during follow-up (24) . Finally, a study of the natural history of HPV infection found that older age, infection with cancer-associated HPV types, and infection with multiple HPVs were associated with persistence (25) . With regard to the consequences of HPV persistence, persistent infection, defined as detection of the same HPV type at two consecutive 3-month visits during a 15-month follow-up, was found to be associated with persistent cervical smear abnormalities (26) .
Previous reports of HPV persistence did not, however, simultaneously incorporate data on HTV serostatus and CD4 + cell count, extended longitudinal HPV measurements, and assessment of cervical neoplasia by colposcopy. Here we have analyzed and presented data from 268 women whose HTV serostatus and CD4 + cell counts were available at baseline, from whom 1,426 specimens were collected semiannually, and on whom colposcopies were performed at the end of study follow-up. The strengths of evaluating disease status using colposcopy at the end of the follow-up period are that colposcopy and biopsy are the gold standard for determination of cervical neoplasia and further that disease status was assessed subsequent to the relevant "exposures" of HTV-associated immunosuppression and repeated HPV positivity. A limitation, however, is that the duration of cervical neoplasia prior to its ascertainment is unknown.
We found that the prevalence of HPV infection was particularly high among immunosuppressed HIVseropositive women, as was the likelihood of repeated HPV infection at follow-up visits. In addition, severely immunosuppressed HTV-seropositive women were less likely and took longer to clear HPV infection in follow-up than did HTV-seronegative women. As for cervical neoplasia, the strong association between HTV serostatus and CIN in our population confirmed previous observations (27) (28) (29) . However, when women were stratified according to level of repeated HPV positivity, this association became negligible, supporting the hypothesis that HTV infection increases risk of CIN via a mechanism modulated by HPV positivity. Furthermore, and as expected, HPV positivity was strongly associated with the likelihood of CIN.
In this study, we have provided measures of how HIV and immunosuppression are related to the repeated positivity of HPV infection and CIN. While the sample size of this study was not large enough to allow precise inferences for each HPV type, in order to incorporate the specificity of repeated positivity (i.e., persistence) by type, we performed HPV type-specific analyses and calculated a weighted average. This approach was analogous to the combination of 2 x 2 tables using the Mantel-Haenszel approach, when the sample sizes of each stratum are only moderate. These estimates confirmed that immunosuppression decreases the incidence of HPV clearance among highrisk types or, conversely, increases the risk of repeated HPV positivity. Detailed examination of type-specific HPVs will require larger cohorts to fully characterize the role of persistence as opposed to repeated HPV positivity in explaining the natural history of HPV in HTV-infected women (30, 31) .
Our findings support the hypothesis that repeated HPV positivity is associated with HIV-induced immunosuppression and suggest that persistence may explain why some HPV-infected women develop CIN while others do not. While we could not investigate possible indirect molecular interactions between HPV and HTV (32), other groups are investigating this alternative, or perhaps complementary, hypothesis. The broader significance of our observations is that other determinants of HPV persistence, including environmental, host, and viral factors, may likewise play an important role in the natural history of HPV disease. If persistence consequent to HTV-associated immunosuppression is confirmed to modulate CIN risk among women infected with HPV, it will be important to investigate other determinants of such persistence toward a more complete understanding of HPV infection. Future studies should more fully characterize the correlates of type-specific persistence, or better yet, the persistence of HPV variants, so that the issue of reactivation of latent infections can be explored. The ultimate aim of such investigations is to more fully explore the possibility that it is those women with persistent HPV infection (for reasons beyond HTV-related immunosuppression) who go on to develop CIN.
Clinically, our findings underscore the importance of ready access to potent antiretrovial therapy for HTVseropositive women, so that immunosuppression can be reversed (33) . In this regard, it is of note that only one of the 11 women found to have CIN had exposure to potent antiretroviral therapy, and she began only 6 months prior to colposcopy. The remaining 10 participants were either therapy naive or had monotherapy. As increasing numbers of women gain access to potent antiretroviral therapy, it is logical to expect that the dramatic reduction in HTV-RNA levels will allow some reconstitution of the immune system and conceivably a reduction in levels of HPV persistence and neoplastic sequelae. A recently published study of 49 women who had colposcopic evaluations prior to and again 5 months following potent antiretroviral therapy found a significant decrease in the prevalence of CIN, suggesting that therapy may play such a role (34) . It will be critical to further examine such possible associations and to determine the impact of antiretroviral medications on the natural history of HPV infection and progression to CIN. Our data suggest that reversing HTV-associated immunosuppression might reduce HPV persistence and consequently the increased risk for cervical neoplasia among HIV-seropositive women. The ideal setting to fully test this hypothesis will be ongoing prospective studies that evaluate HPV infection, cervical neoplasia, and medication use longitudinally.
